繁體版 / 簡體版
 
R&D PORTFOLIO
/ SNP-830、SNP-840

SNP-830、SNP-840

Indication
Hepatotoxicity-free Analgesic
Product Advantages
1. Hepatotoxicity-free Acetaminophen prescription Combo
2. A new combination with great safety margin
Status
After the approval of SNP-810 Plan a clinical trial with / without bioequivalent study for NDA
Competitive Edge
1. No hepatotoxicity-free acetaminophen prescription Combo on the market
2. Acetaminophen prescription combos were requested by USFDA to reduce the dose to below 325 mg ( potency affected )
3. Remove or modify the FDA liver warning
4. Regain the AAP dose to 500 mg or more
5. Grab the market of other pain controllers
6. The two choose one license
Potential Market
Acetaminophen prescription Combo sales are 2.7 billion USD a year (US only)


好玩棋牌 pk10稳赢技巧 陕西11选5走势图表 赚钱小项目适合女生的 威海 配资炒股 利息 重庆快乐10分计划软件 吉林快3微信群 夜盘配资公司 北京时时彩的官网下载 彩票开奖结果查询公告 河南快3开奖视频直播